INCY Incyte Corp.

Incyte to Report Third Quarter Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 10:00 a.m. ET on Tuesday, October 31, 2017.

The schedule for the press release and conference call/webcast is as follows:

 

• Q3 2017 Press Release:

October 31, 2017 at 7:00 a.m. ET

• Q3 2017 Conference Call:

October 31, 2017 at 10:00 a.m. ET

• Domestic Dial-In Number:

877-407-3042

• International Dial-In Number:

201-389-0864

• Conference ID Number:

13672268
 

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13672268.

The live webcast with slides can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

12/10/2017
0 pages
EN

Research Provider

Business Wire, acquired by Berkshire Hathaway in 2006, is the global market leader in commercial news distribution. Thousands of member companies and organisations depend on Business Wire to transmit their full-text press releases, regulatory filings, photos and other multimedia content to journalists, financial professionals, investor services, regulatory authorities and consumers worldwide. For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.


Read more

Underlying

Health Care - United States

Incyte is a biopharmaceutical company focused on developing and commercializing proprietary therapeutics. The company's portfolio includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized products JAKAFIr (ruxolitinib) and ICLUSIGr (ponatinib). JAKAFI (ruxolitinib) is for the treatment of patients with intermediate or high-risk myelofibrosis and for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. ICLUSIG is a kinase inhibitor targeted for BCR-ABL, an abnormal tyrosine kinase in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.

Read more

ResearchPool Subscriptions

Get the most out of your insights

Get in touch